September 2024 - Page 10 of 156

Canadian Stock Exchange News - September 30, 2024

Foremost Announces Date for its Annual General and Special Meeting to Approve the Spin-Out of the Winston Group of Gold and Silver Properties

Highlights Shareholders of record on November 06, 2024 to vote at Shareholder meeting to be held on December 09, 2024 […]

TSX News - September 30, 2024

Eloro Resources Receives Lead Order from Strategic Investor Crescat Capital and Announces Non-Brokered Private Placement Offering Up to $2,700,000

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE […]

NASDAQ Companies - September 30, 2024

Worksport Provides Progress Update on ISO 9000 Certification

ISO Certification paves the way to OEM relationships which could include direct and indirect sales to global car makers such […]

NASDAQ Companies - September 30, 2024

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or […]

NYSE Companies - September 30, 2024

ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health

ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by […]

NASDAQ Companies - September 30, 2024

Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today […]

NYSE Companies - September 30, 2024

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic […]

Foremost Announces Date for its Annual General and Special Meeting to Approve the Spin-Out of the Winston Group of Gold and Silver Properties

Eloro Resources Receives Lead Order from Strategic Investor Crescat Capital and Announces Non-Brokered Private Placement Offering Up to $2,700,000

Worksport Provides Progress Update on ISO 9000 Certification

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health

Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024

AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting

Integer Holdings Corporation to Divest Non-Medical Business for $50 million

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma